文献速递脊柱关节炎

轴性脊柱关节炎合并症与TNF抑制剂应答:BSRBR-AS纵向分析

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

研究基于英国国家axSpA注册数据,分析994例首次使用TNFi患者,发现合并症多者基线病情更重,但BASDAI和脊柱疼痛绝对改善与无合并症者相当;≥2种合并症者BASFI和生活质量改善更小,治疗停药风险增加。

要点

  • 合并症负担重者基线疾病活动度和功能损害更重。
  • ≥2种合并症者BASFI和生活质量绝对改善更小。
  • ≥3种合并症者治疗停药风险显著增加(HR 2.18)。

核心结论

  • 多种合并症患者TNFi治疗结局较差,尤其治疗停药增加及功能和生活质量改善更差。

研究设计与样本

  • 基于国家axSpA注册的前瞻性队列,纳入994例首次使用TNFi的axSpA患者(68%男性,平均年龄45岁)。
  • 合并症由14种医生诊断疾病归类,采用线性混合模型、logistic模型和Cox模型分析,调整年龄、性别、BMI、贫困和教育程度。

主要发现

  • 21%患者有1种合并症,11%有≥2种合并症;有合并症者所有疾病指数基线严重度更高。
  • BASDAI和脊柱疼痛的绝对改善在有无合并症者间相当。
  • ≥2种合并症者BASFI和生活质量绝对改善更小。
  • ≥2种合并症者达到BASDAI50/2的OR为0.81(95%CI 0.45,1.45),BASDAI<4的OR为0.57(95%CI 0.32,1.04)。
  • 与无合并症者相比,2种合并症者停药HR为1.32(95%CI 0.88,2.00),≥3种合并症者HR为2.18(95%CI 1.20,3.93)。

关键数值与推荐

  • BASDAI50/2定义为BASDAI改善50%或下降2个单位;BASDAI<4为6个月时低疾病活动度标准。
  • 合并症分类基于14种医生诊断疾病。

临床怎么用

  • 临床中应评估axSpA患者合并症负担,对多种合并症者预期功能和生活质量改善较小且停药风险更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Comorbidities influence disease assessment in axial spondyloarthritis (axSpA), but their association with response to TNF inhibitors (TNFi) is unclear. We examined associations between comorbidity history at TNFi initiation and: (i) change in disease indices over time; (ii) binary response definitions; and (iii) time to treatment discontinuation. METHODS: We studied participants starting their first TNFi from a national axSpA register. Comorbidity categories were created from 14 physician-diagnosed conditions and compared against: change in disease indices over time using linear mixed effects models; BASDAI50/2 (50% or 2-unit reduction) and BASDAI < 4 at 6 months using logistic models; and time to treatment discontinuation using Cox models. Models were adjusted for age, gender, BMI, deprivation and education. RESULTS: In total, 994 were eligible for analysis (68% male, mean age 45 years); 21% had one comorbidity and 11% had ≥2. Baseline disease severity was higher in those with comorbidities across all indices, but absolute improvement over time was comparable for BASDAI and spinal pain. Participants with ≥2 comorbidities had smaller absolute improvement in BASFI and quality of life. This group also had numerically reduced odds of achieving BASDAI50/2 [odds ratio (OR) 0.81; 95% CI: 0.45, 1.45] and BASDAI < 4 (OR 0.57; 95% CI: 0.32, 1.04). Treatment discontinuation was increased in those with two comorbidities [hazard ratio (HR) 1.32; 95% CI: 0.88, 2.00] and ≥3 comorbidities (HR 2.18; 95% CI: 1.20, 3.93) compared with none. CONCLUSIONS: Participants with multiple comorbidities had poorer treatment outcomes, particularly increased treatment discontinuation and poorer improvements in function and quality of life. These results inform clinicians and educate patients about response to the first TNFi given comorbidity burden.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zhao SS, Jones GT, Macfarlane GJ, et al. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford). 2021. PMID: 33369676. doi:10.1093/rheumatology/keaa900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。